Avelumab resistance management

Avelumab (Avelumab) is an immunotherapy drug used to treat many types of cancer. The principle of action of avelumab is to block the interaction between PD-L1 and its receptors PD-1 and B7.1, thereby releasing the inhibitory effect of PD-L1 on immune responses and restoring immune responses, including anti-tumor immune responses. However, sometimes patients may develop drug resistance, that is, the drug's effect on cancer cells is weakened or completely ineffective.

For managing resistance to avelumab, here are some possible approaches: Combining avelumab with other drugs or immunotherapy drugs to enhance the effectiveness of the treatment. This can include combinations with other immune checkpoint inhibitors or chemotherapy drugs. The therapeutic dose of avelumab is adjusted based on the patient's specific condition. Sometimes, increasing the dose of a drug may help overcome resistance. If avelumab fails, you may need to consider switching to other treatments, such as targeted therapy, chemotherapy, or radiotherapy. However, drug resistance treatment methods should be determined based on the patient's individual situation and the doctor's recommendations, because everyone's constitution is different and their drug resistance responses are also different.

Avelumab is an emerging cancer treatment drug. The original drug has not yet been marketed in China, so it cannot be included in medical insurance. The price of Avelumab's generic drug, 200mg/10mL per box, may be more than RMB 10,000 per box (the price may fluctuate due to the exchange rate). We are not aware of any Avelumab generics being produced and put on the market. For specific prices and drug details, please consult Yade's medical consultant.